MX347101B - Forma de dosis de disolucion rapida de vacuna oral que usa almidon. - Google Patents

Forma de dosis de disolucion rapida de vacuna oral que usa almidon.

Info

Publication number
MX347101B
MX347101B MX2013003875A MX2013003875A MX347101B MX 347101 B MX347101 B MX 347101B MX 2013003875 A MX2013003875 A MX 2013003875A MX 2013003875 A MX2013003875 A MX 2013003875A MX 347101 B MX347101 B MX 347101B
Authority
MX
Mexico
Prior art keywords
starch
dosage form
dissolving dosage
oral vaccine
fast
Prior art date
Application number
MX2013003875A
Other languages
English (en)
Other versions
MX2013003875A (es
Inventor
Tian Wei
Mclaughlin Rosie
Original Assignee
Scherer Technologies Llc R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Technologies Llc R P filed Critical Scherer Technologies Llc R P
Publication of MX2013003875A publication Critical patent/MX2013003875A/es
Publication of MX347101B publication Critical patent/MX347101B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una forma de dosis de vacuna sólida, oral, de disolución rápida, caracterizada porque comprende: (a) una cantidad inmunogénica de una preparación antigénica; y (b) al menos un agente formador de matriz, potenciador de respuesta inmunitaria, en donde por lo menos un agente formador de matriz, potenciador o respuesta inmunitaria es un almidón, y en donde la forma de dosis facilita absorción de cavidad oral de un antígeno dentro de la preparación antigénica.
MX2013003875A 2010-10-08 2011-10-11 Forma de dosis de disolucion rapida de vacuna oral que usa almidon. MX347101B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39123810P 2010-10-08 2010-10-08
PCT/US2011/055689 WO2012048333A1 (en) 2010-10-08 2011-10-11 Oral vaccine fast-dissolving dosage form using starch

Publications (2)

Publication Number Publication Date
MX2013003875A MX2013003875A (es) 2013-06-24
MX347101B true MX347101B (es) 2017-04-12

Family

ID=44908091

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017004866A MX386380B (es) 2010-10-08 2011-10-11 Forma de dosis de disolución rápida de vacuna oral que usa almidón.
MX2013003875A MX347101B (es) 2010-10-08 2011-10-11 Forma de dosis de disolucion rapida de vacuna oral que usa almidon.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017004866A MX386380B (es) 2010-10-08 2011-10-11 Forma de dosis de disolución rápida de vacuna oral que usa almidón.

Country Status (17)

Country Link
US (1) US9956169B2 (es)
EP (2) EP2624815B8 (es)
JP (2) JP6061859B2 (es)
KR (1) KR101751964B1 (es)
CN (2) CN108434089B (es)
AR (1) AR083361A1 (es)
AU (1) AU2011312107B2 (es)
BR (1) BR112013009255B1 (es)
CA (1) CA2813146C (es)
DK (2) DK3095441T3 (es)
ES (2) ES2842290T3 (es)
HU (1) HUE052853T2 (es)
MX (2) MX386380B (es)
PL (1) PL3095441T3 (es)
PT (1) PT3095441T (es)
RU (2) RU2639447C2 (es)
WO (1) WO2012048333A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6061859B2 (ja) * 2010-10-08 2017-01-18 アール．ピー． シェーラー テクノロジーズ エルエルシー デンプンを使用する経口ワクチン速溶性剤型
US10272038B2 (en) 2013-12-02 2019-04-30 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
US11033493B2 (en) 2013-12-02 2021-06-15 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
US9668970B2 (en) * 2013-12-02 2017-06-06 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
TWI745278B (zh) * 2014-10-10 2021-11-11 以色列商艾畢克生物實驗有限公司 發泡性降低之疫苗組合物
CN104530489B (zh) * 2015-02-05 2017-07-07 湖南尔康制药股份有限公司 一种速溶于水的淀粉成膜组合物
CN109224191A (zh) * 2018-07-23 2019-01-18 西安交通大学医学院第附属医院 一种用于静脉输液用的无菌输液港辅助植入装置
US11523988B2 (en) * 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
HUE056569T2 (hu) 2019-07-31 2022-02-28 Catalent Uk Swindon Zydis Ltd Sûrûség-áramlásmérõ gyógyászati készítmény adagolásához
EP4213805A1 (en) 2020-09-17 2023-07-26 Catalent U.K. Swindon Zydis Limited Use of surfactant with high molecular weight fish gelatin based dosage formulations to improve flow characteristics
WO2022074127A2 (en) 2020-10-08 2022-04-14 Catalent U.K. Swindon Zydis Limited Stable oral dispersible formulation for epinephrine and salts or solvates thereof
EP4243602A4 (en) 2020-11-16 2024-11-13 Orcosa Inc. Improved use of cannabinoids in the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2026024894A2 (en) 2024-07-24 2026-01-29 De Alba Jorge Sublingual formulations of a peptide derived from chaperonin 60.1 and related methods

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
IT1250421B (it) 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
JPH08508247A (ja) 1993-03-11 1996-09-03 セクレテック，インク． 粘膜表面への免疫原の輸送における重合的粘膜付着体
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
WO1997013531A1 (en) * 1995-10-13 1997-04-17 Zynaxis, Inc. Solid, orally administrable viral vaccines and methods of preparation
GB9700878D0 (en) * 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
EP1579851A3 (en) * 1997-08-29 2009-09-02 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of use thereof
US20040265377A1 (en) * 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
GB9722682D0 (en) 1997-10-27 1997-12-24 Scherer Ltd R P Pharmaceutical products
GB9901819D0 (en) * 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
ES2315244T3 (es) * 1999-11-12 2009-04-01 Fibrogen, Inc. Gelatina recombinante en vacunas.
EP1120109A3 (en) * 2000-01-24 2002-07-10 Pfizer Products Inc. Rapidly disintegrating and fast dissolving solid dosage form
GB0020089D0 (en) 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
US6509040B1 (en) * 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
CA2484724C (en) * 2002-05-07 2007-01-16 Ferring B.V. Pharmaceutical formulations
SG172476A1 (en) 2002-08-12 2011-07-28 Dynavax Tech Corp Immunomodulatory compositions comprising a cationic condensing agent, an immunostimulatory compound comprising 5'-cg-3', an a non ionic detergent
MXPA05005528A (es) 2002-11-26 2006-04-05 Alk Abello As Producto farmaceutico de alergeno.
US8012505B2 (en) * 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
JP2006525308A (ja) * 2003-05-02 2006-11-09 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 耐熱性および耐湿性が改善された変性デンプンを含有する速溶性の経口消耗フィルム
JP5097400B2 (ja) * 2003-09-03 2012-12-12 デンドリセラピューティクス、インク． 複合ワクチン
US7972621B2 (en) * 2004-06-03 2011-07-05 R.P. Scherer Technologies, Llc Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
AU2006299310A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
US20070166239A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
US20110129438A1 (en) 2006-06-28 2011-06-02 James Robert Swartz Immunogenic protein constructs
BRPI0815662A2 (pt) * 2007-08-20 2016-09-27 Fraunhofer Usa Inc vacinas, antígenos, composições, e métodos profilácticos e terapêuticos para gripe
US20090226522A1 (en) * 2008-02-28 2009-09-10 Howes Simon A M Process to minimize polymorphism
US20110305768A1 (en) * 2008-07-01 2011-12-15 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
US20120034253A1 (en) * 2008-09-25 2012-02-09 Fraunhofer Usa, Inc. Influenza Vaccines, Antigens, Compositions, and Methods
KR101074271B1 (ko) * 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름
US8545879B2 (en) * 2009-08-31 2013-10-01 Wilmington Pharmaceuticals, Llc Fast disintegrating compositions of meloxicam
ES2712989T3 (es) * 2009-10-30 2019-05-17 Ix Biopharma Ltd Forma de dosificación sólida de disolución rápida
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
EP2590516B1 (en) * 2010-07-08 2017-11-29 Wm. Wrigley Jr. Company Confection with gelatin-polyphenol complex
JP6061859B2 (ja) * 2010-10-08 2017-01-18 アール．ピー． シェーラー テクノロジーズ エルエルシー デンプンを使用する経口ワクチン速溶性剤型

Also Published As

Publication number Publication date
EP3095441A1 (en) 2016-11-23
RU2639447C2 (ru) 2017-12-21
KR101751964B1 (ko) 2017-06-28
HK1253541A1 (zh) 2019-06-21
AR083361A1 (es) 2013-02-21
EP2624815B8 (en) 2016-09-21
BR112013009255B1 (pt) 2021-02-23
CN108434089A (zh) 2018-08-24
EP2624815B1 (en) 2016-08-10
EP3095441B1 (en) 2020-12-02
CN103347494A (zh) 2013-10-09
RU2013119946A (ru) 2014-11-20
PT3095441T (pt) 2021-01-14
CA2813146C (en) 2018-12-18
DK2624815T3 (en) 2016-11-07
RU2017137357A3 (es) 2019-04-25
ES2842290T3 (es) 2021-07-13
EP2624815A1 (en) 2013-08-14
US9956169B2 (en) 2018-05-01
BR112013009255A2 (pt) 2016-07-26
RU2017137357A (ru) 2019-04-25
CA2813146A1 (en) 2012-04-12
JP6403738B2 (ja) 2018-10-10
MX386380B (es) 2025-03-18
JP2013539766A (ja) 2013-10-28
JP6061859B2 (ja) 2017-01-18
ES2602506T3 (es) 2017-02-21
US20120087944A1 (en) 2012-04-12
DK3095441T3 (da) 2021-01-11
AU2011312107A1 (en) 2013-05-02
KR20140091461A (ko) 2014-07-21
AU2011312107B2 (en) 2016-06-23
WO2012048333A1 (en) 2012-04-12
PL3095441T3 (pl) 2021-06-14
CN108434089B (zh) 2020-06-16
MX2013003875A (es) 2013-06-24
JP2016199605A (ja) 2016-12-01
HUE052853T2 (hu) 2021-05-28

Similar Documents

Publication Publication Date Title
MX347101B (es) Forma de dosis de disolucion rapida de vacuna oral que usa almidon.
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
NZ707377A (en) Combination therapy methods for treating proliferative diseases
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
MX2019007956A (es) Liberacion autorregulada de ingrediente farmaceutico activo.
CL2016002132A1 (es) Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
IN2012DN06309A (es)
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX363495B (es) Proceso de manufacturacion de una forma de dosificacion multifasica de rapida disolucion liofilizada.
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
EA201391689A1 (ru) Система доставки лекарственного средства
DK201270677A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
MX2015007912A (es) Inhalador de polvo seco y metodo de uso.
MX2024013184A (es) Metodos y composiciones para tratar apnea del sue?o
MX2015007678A (es) Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales.
DK2802319T3 (da) Fastdosiskombinationsterapi for parkinsons sygdom
GB201014391D0 (en) Drug composition and its use in therapy
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
UA105944C2 (uk) Комбінація теоброміну з деконгестантом і її застосування для лікування кашлю
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
MY198201A (en) A Combination Medicament Comprising Phenylephrine And Paracetamol

Legal Events

Date Code Title Description
FG Grant or registration